Indices: Stock market update: Nifty Pharma index advances 1.03%
The Nifty Pharma index closed 1.03 per cent up at 16562.6.
Stay updated with breaking news from Biocon Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Nifty Pharma index closed 1.03 per cent up at 16562.6.
Adalimumab BS for subcutaneous injection is indicated for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.
Adalimumab BS for subcutaneous injection is a biosimilar of Humira, offering therapeutic solutions for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn's disease and ulcerative colitis
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), signed today a Distribution Agreement with Sandoz, granting the Company the exclusive rights to promote, sell and
The Nifty Pharma index was trading 0.75 per cent down at 16000.05.